Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

OncoSec Medical Incorporated (ONCS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8800+0.0298 (+3.51%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7579
Open0.7700
Bid0.8550 x 1100
Ask0.7599 x 1100
Day's Range0.7300 - 0.7797
52 Week Range0.6700 - 4.2500
Volume40,259
Avg. Volume85,828
Market Cap34.614M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1600
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
  • PR Newswire

    OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer (TNBC) Foundation. OncoSec's Head of Patient Advocacy, Kimberly Irvine, will accept the award on behalf of the Company at the Foundation's gala titled, "No One Fights Alone," on May 25, 2022.

  • PR Newswire

    OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer.

  • PR Newswire

    OncoSec Announces Appointment of George Chi as Chief Financial Officer

    OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer.

Advertisement
Advertisement